Reece Armstrong examines the advances being made in identifying cell surface proteins and what this means for cancer drug discovery. There have been some landmark FDA approvals in recent years – but not everyone has picked up on the significance of its decision to green-light Merus’ lung and pancreatic cancer drug Bizengri (zenocutuzumab). Approved for […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!